Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension

Next Previous
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Prospective, Multicenter, Parallel Group Study to Assess the Safety and Efficacy of Macitentan in Patients With Portopulmonary Hypertension

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Macitentan (Primary)
  • Indications Portal hypertension; Pulmonary arterial hypertension
  • Focus Therapeutic Use
  • Acronyms PORTICO
  • Sponsors Actelion Pharmaceuticals

Most Recent Events

  • 09 Mar 2020 Results of post hoc exploratory analyses conducted on full set analysis (all randomized participants) for double-blind treatment period assessing implications of hemodynamics changes in patients with post pulmonary hypertension published in the Liver Transplantation
  • 19 Dec 2018 Status changed from active, no longer recruiting to completed.
  • 13 Nov 2018 Results assessing efficacy and safety presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top